These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


753 related items for PubMed ID: 23407458

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G.
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [Abstract] [Full Text] [Related]

  • 3. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G.
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [Abstract] [Full Text] [Related]

  • 4. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V.
    J Clin Oncol; 2008 Jan 10; 26(2):283-9. PubMed ID: 18182669
    [Abstract] [Full Text] [Related]

  • 5. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession A, Rondelli R, De Rossi G, Lo Nigro L, Porta F, Santoro N, Indolfi P, Basso G, Conter V, Aricò M, Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Haematologica; 2001 May 10; 86(5):478-84. PubMed ID: 11410410
    [Abstract] [Full Text] [Related]

  • 6. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb 10; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 7. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.
    Ann Hematol; 2014 Oct 10; 93(10):1677-84. PubMed ID: 24863691
    [Abstract] [Full Text] [Related]

  • 8. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
    Pillon M, Aricò M, Basso G, Locatelli F, Citterio M, Micalizzi C, Testi AM, Barisone E, Nardi M, Lombardi A, Rondelli R, Rosolen A, NHL-Committee of the Italian Association of Pediatric Hematology, Oncology.
    Pediatr Blood Cancer; 2011 Apr 10; 56(4):544-50. PubMed ID: 21298738
    [Abstract] [Full Text] [Related]

  • 9. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.
    Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N, Uderzo C, Fagioli F, Conter V, Bonetti F, Favre C, Porta F, Giorgiani G, Pession A.
    Leukemia; 2002 Nov 10; 16(11):2228-37. PubMed ID: 12399966
    [Abstract] [Full Text] [Related]

  • 10. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A, Lauten M, Beier R, Odenwald E, Stanulla M, Zimmermann M, Attarbaschi A, Niggli F, Schrappe M.
    Klin Padiatr; 2013 May 10; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V, Schrappe M, Aricó M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmermann M, Ludwig WD, Basso G, Masera G, Riehm H.
    J Clin Oncol; 1997 Aug 10; 15(8):2786-91. PubMed ID: 9256120
    [Abstract] [Full Text] [Related]

  • 13. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H, Kawakami K, Ayukawa H, Akiyoshi K, Kamizono J, Tamai Y, Kinukawa N, Okamura J.
    Med Pediatr Oncol; 2001 Jul 10; 37(1):10-9. PubMed ID: 11466717
    [Abstract] [Full Text] [Related]

  • 14. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G.
    Leukemia; 2008 Dec 10; 22(12):2193-200. PubMed ID: 18754029
    [Abstract] [Full Text] [Related]

  • 15. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies.
    Vecchi V, Aricò M, Basso G, Ceci A, Madon E, Mandelli F, Masera G, Massimo L, Pession A, Zanesco L.
    Cancer; 1993 Oct 15; 72(8):2517-24. PubMed ID: 8402470
    [Abstract] [Full Text] [Related]

  • 16. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G, v Stackelberg A, Eckert C.
    Klin Padiatr; 2013 May 15; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [Abstract] [Full Text] [Related]

  • 17. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
    Aricò M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, Barisone E, Poggi V, De Rossi G, Locatelli F, Micalizzi MC, Basso G, Masera G.
    Blood; 2002 Jul 15; 100(2):420-6. PubMed ID: 12091331
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M.
    Klin Padiatr; 2005 Jul 15; 217(6):310-20. PubMed ID: 16307416
    [Abstract] [Full Text] [Related]

  • 19. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 38.